Zhou Su-Fang, Xie Xiao-Xun, Bin Ye-Hong, Lan Lin, Chen Fang, Luo Guo-Rong
The School of Pre-clinical Sciences, Guangxi Medical University, 22 Shuangrong Road, Nanning 530021, China.
Clin Chim Acta. 2006 Apr;366(1-2):274-80. doi: 10.1016/j.cca.2005.10.026. Epub 2005 Dec 13.
Serological identification of antigens by recombinant expression cloning (SEREX) is a promising method used to analyze tumor-associated antigen (TAA). Nineteen primary HCC-associated antigens have been found from a HCC cDNA library using autogenous serum by the SEREX approach. We searched for HCC-associated antigens and applied them to HCC diagnosis.
Nine of 19 primaries HCC-associated antigens identified by SEREX method were tested their immune response again with distinct allogeneic sera. One of the screened HCC-associated antigens, HCC-22-5 was recombined and expressed and made the frequency analysis of its seropositivity in various patients using the methods of Western-blot and ELISA.
SEREX analysis showed that 9 primary HCC-associated antigens had high-titered IgG antibody in the majority of HCC patients. Western-Blot method confirmed that 3/7 HCC patients had antibodies against HCC-22-5, which demonstrated that expressed HCC-22-5 antigen had the character of antigen. Sera samples from 341 patients and 80 normal individuals have been tested for autoantibodies against HCC-22-5 by ELISA method. The results found that 51/128 of HCC, 11/76 of chronic hepatitis, 11/22 of liver cirrhosis and 8/54 of nasopharynx cancer patients had antibodies against HCC-22-5. No antibody response to HCC-22-5 had been found in the sera of 7 lung cancers, 54 gastric-intestine patients and 80 normal individuals. The groups of HCC and liver cirrhosis had higher antibody positive rate than that of other groups (p<0.05). In the HCC sera with alpha-fetoprotein (AFP) negative, the positive rate of HCC-22-5 was as high as 78.9%.
HCC-22-5 can be used for HCC serologic screening, especially for the patients with AFP negative.
通过重组表达克隆进行抗原的血清学鉴定（SEREX）是一种用于分析肿瘤相关抗原（TAA）的有前景的方法。利用SEREX方法，通过自体血清从肝癌cDNA文库中发现了19种原发性肝癌相关抗原。我们寻找肝癌相关抗原并将其应用于肝癌诊断。
对通过SEREX方法鉴定出的19种原发性肝癌相关抗原中的9种，再次用不同的同种异体血清检测其免疫反应。筛选出的一种肝癌相关抗原HCC-22-5进行重组表达，并用蛋白质印迹法和酶联免疫吸附测定法对其在不同患者中的血清阳性率进行频率分析。
SEREX分析显示，9种原发性肝癌相关抗原在大多数肝癌患者中具有高滴度IgG抗体。蛋白质印迹法证实，7例肝癌患者中有3例具有抗HCC-22-5抗体，这表明表达的HCC-22-5抗原具有抗原特性。采用酶联免疫吸附测定法对341例患者和80例正常个体的血清样本进行了抗HCC-22-5自身抗体检测。结果发现，128例肝癌患者中有51例、76例慢性肝炎患者中有11例、22例肝硬化患者中有11例以及54例鼻咽癌患者中有8例具有抗HCC-22-5抗体。在7例肺癌患者、54例胃肠道疾病患者和80例正常个体的血清中未发现对HCC-22-5的抗体反应。肝癌组和肝硬化组的抗体阳性率高于其他组（p<0.05）。在甲胎蛋白（AFP）阴性的肝癌血清中，HCC-22-5的阳性率高达78.9%。
HCC-22-5可用于肝癌的血清学筛查，尤其是对AFP阴性的患者。
